Dear ASN Members: I would like to share some exciting new A new section has been added to the website entitled “Editor's Choice’ which will highlight recent articles. Current highlights cover two recent reviews “Shedding Light on the Dark Side of the Microglia” and “NRF2 as a Therapeutic Target in Neurodegenerative Diseases”, an original article describing selective neuronal loss in AD mouse models “Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease”, and a commentary on therapeutic approaches for Alzheimer’s disease "Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle”. ASN Officers and Council want to thank all the ASN members who have contributed to the success of our journal, and hope you will continue to read, recommend, and submit manuscripts. Remember that ASN members receive 50% discount on all page charges. Sincerely, Terri Wood, ASN President Douglas Feinstein, Editor-in-Chief ASNeuro |